Vor Biopharma Inc.
NASDAQVor Biopharma reports Q1 2026 results on June 11 carrying one of the most conspicuous short positions in its peer group — and a significant institutional seller who has already voted with their feet. Short interest is the most pressing part of this setup. Bears hold 23% of the free float short, a level that has risen roughly 8% over the past month and now sits near its highest…
Snapshot as of 10 Jun 2026
Vor Biopharma reports Q1 2026 results on June 11 carrying one of the most conspicuous short positions in its peer group — and a significant institutional seller who has already voted with their feet. Short interest is…
VOR heads into a compressed earnings cycle with short sellers accelerating positions, a freshly reported Q1 beat, and another update due in less than a week. Short interest has been the defining story of the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for VOR — free to start on ORTEX.
Sign up for free →Open VOR on ORTEX